Creatine monohydrate pilot in Alzheimer's: Feasibility, brain creatine, and cognition
Alzheimer's & Dementia: Translational Research & Clinical Interventions · 2025-04 · 11 (2)
DOI: 10.1002/trc2.70101 ↗At a glance
Journal article in Alzheimer's & Dementia: Translational Research & Clinical Interventions, published online on 2025-05-19. Written by Aaron N Smith and 7 co-authors. Institution: Department of Dietetics & Nutrition University of Kansas Medical Center, 3901 Rainbow Blvd. Kansas City Kansas USA. Cited 17 times so far (Crossref); 41 references. The full text is freely available (open access, CC BY-NC 4.0). Funded by: NIA NIH HHS, NCATS NIH HHS, Alzheimer's Association.
Topics: Demenz
Abstract (original language)
BACKGROUND Preclinical studies suggest that creatine monohydrate (CrM) improves cognition and Alzheimer's disease (AD) biomarkers. However, there is currently no clinical evidence demonstrating the effects of CrM in patients with AD. METHODS In this single‐arm pilot trial, we investigated the feasibility of 20 g/day CrM for 8 weeks in 20 patients with AD. We measured compliance throughout; serum creatine at baseline, 4 weeks, and 8 weeks; and brain total creatine (tCr) and cognition (National Institutes of Health [NIH] Toolbox, Mini‐Mental State Examination [MMSE]) at baseline and 8 weeks. RESULTS Nineteen participants achieved the target of ≥80% compliance with the CrM intervention. Serum Cr was elevated at 4 and 8 weeks ( p < .001) and brain tCr increased by 11% ( p < .001). Cognition improved on global ( p = .02) and fluid ( p = .004) composites, List Sorting ( p = .001), Oral Reading ( p < .001), and Flanker ( p = .05) tests. DISCUSSION Our data suggest that CrM supplementation is feasible in AD and provides preliminary evidence for future efficacy and mechanism studies. Trial Registration ClinicalTrials.gov, NCT05383833, registered on May 20, 2022. Highlights Creatine monohydrate supplementation was feasible in patients with Alzheimer's disease. Creatine monohydrate was associated with increased brain total creatine. Creatine monohydrate was associated with improvements in cognition. Efficacy of creatine monohydrate in Alzheimer's disease should be studied further.
Subjects
Author keywords
Authors and institutions
- Department of Dietetics & Nutrition University of Kansas Medical Center, 3901 Rainbow Blvd. Kansas City Kansas USA.
- Department of Neurology University of Kansas Medical Center, 3901 Rainbow Blvd. Kansas City Kansas USA.
- Department of Radiology University of Kansas Medical Center, 3901 Rainbow Blvd. Kansas City Kansas USA.
- Hoglund Biomedical Imaging Center University of Kansas Medical Center, 3901 Rainbow Blvd. Kansas City Kansas USA.
- Department of Cell Biology & Physiology University of Kansas Medical Center, 3901 Rainbow Blvd. Kansas City Kansas USA.
- Alzheimer's Disease Research Center University of Kansas, 4350 Shawnee Mission Pkwy Fairway Kansas City Kansas USA.
Funding
- NIA NIH HHS
- NCATS NIH HHS
- Alzheimer's Association
- National Institutes of Health
Cite
APA
Smith, A. N., Choi, I. Y., Lee, P., Sullivan, D. K., Burns, J. M., Swerdlow, R. H., Kelly, E., & Taylor, M. K. (2025). Creatine monohydrate pilot in Alzheimer's: Feasibility, brain creatine, and cognition. Alzheimer's & Dementia: Translational Research & Clinical Interventions, 11(2). https://doi.org/10.1002/trc2.70101
Vancouver
Smith AN, Choi IY, Lee P, Sullivan DK, Burns JM, Swerdlow RH, et al. Creatine monohydrate pilot in Alzheimer's: Feasibility, brain creatine, and cognition. Alzheimer's & Dementia: Translational Research & Clinical Interventions. 2025;11(2). doi:10.1002/trc2.70101
BibTeX
@article{Smith2025,
author = {Smith, Aaron N and Choi, In-Young and Lee, Phil and Sullivan, Debra K and Burns, Jeffrey M and Swerdlow, Russell H and Kelly, Emma and Taylor, Matthew K},
title = {Creatine monohydrate pilot in Alzheimer's: Feasibility, brain creatine, and cognition},
journal = {Alzheimer's & Dementia: Translational Research & Clinical Interventions},
year = {2025},
volume = {11},
number = {2},
doi = {10.1002/trc2.70101}
}
EUVIMED